>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow ELECTRIC CO-OP CUTS COSTS WITH NEW 10/4 WORK WEEK

ELECTRIC CO-OP CUTS COSTS WITH NEW 10/4 WORK WEEK Print E-mail
November 14, 2008 11:00 pm

By Valliant Corley

Pilot staff writer

The first few days of Coos-Curry Electric Cooperative 10-hour, four-day work schedule has "been hugely favorable," General Manager Roger Meader said at last week's town hall meeting in Brookings.

The co-op began workdays of 7 a.m. to 5:30 p.m. at the beginning of November. The four-day work week runs from Monday through Thursday, with a three-day weekend.

When the change was approved, Meader predicted the co-op would benefit from the cost-savings expected in the form of reduced fuel consumption, wear and tear on vehicles, employee travel, and the costs to operate the offices.

"With the way our service territory is spread out, we expect the longer work days to allow for greater productivity," Meader said.

He said it took the same amount of time to gather materials from the warehouse in the morning and travel to the job site. But once the crews are there, he predicted there would be more time to actually do the work, saving on travel time and fuel costs.

"In the December board meeting, we will look at the miles driven, gas, electrical usage, overtime for in-house people and overtime for work crews," he said. "We will be reporting to the board all the compliments and complaints. If it doesn't help us save money, three or four months out, we will probably reverse it."

He said if an outage occurs on Friday, it will now be overtime.

"The tree trimming crews that are contracted will stay at a five-day week," Meader said. "They travel on their own time."

 

Business News by Yahoo Finance

  • Economy seen regaining muscle in second quarter
    U.S. economic growth likely regained steam in the second quarter as activity picked up broadly, which would bolster expectations for a stronger performance in the last six months of the year. Gross domestic product likely grew at a 3.0 percent annual rate after shrinking at a 2.9 percent pace in the first quarter, according to a Reuters survey of economists. "I don't think the contraction we saw in the first quarter is reflective of what's truly going on in the economy," said Gus Faucher, senior economist at PNC Financial Services Group in Pittsburgh. Earlier in the second quarter, growth estimates were as high as 4 percent, but they were cut as trade, consumer spending and business investment rebounded from the winter slump by less than expected.
  • Asian shares hit six and a half year high, dollar steady before Fed
    Asian shares touched a six-and-half-year peak on Wednesday and the dollar was steady, with investors waiting for second quarter U.S. growth data as well as a U.S. Federal Reserve meeting that some believe might yield a more hawkish policy outlook. The Fed will not be updating its economic forecasts and Chair Janet Yellen will not hold a news conference following the two-day policy meeting, leaving investors' focus squarely on a statement scheduled to be released at 2 p.m. (18:00 GMT).
  • AstraZeneca buys Almirall lung drugs for up to $2.1 billion
    AstraZeneca (AZN.L) took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's (ALM.MC) lung drugs. The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer (PFE.N) in May, said it would pay an initial $875 million and up to $1.22 billion more if the drugs meet development and sales targets. The tie-up boosts a key therapeutic area for AstraZeneca, whose Chief Executive Pascal Soriot is determined to show his company has a strong independent future. Soriot also struck a clinical trial collaboration with Japan's Kyowa Hakko Kirin (4151.T) for a study that will evaluate a combination of the two companies' drugs in cancer - another important field for AstraZeneca.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use